Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to uncover hidden clues in myasthenia gravis

NCT ID NCT07571525

Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will follow 40 adults with thymic abnormalities or myasthenia gravis (MG)-related antibodies to better understand how the disease develops and progresses. Researchers will analyze blood, thymus tissue, and muscle samples, along with clinical assessments, to link immune markers with nerve-muscle junction damage. Participants will be monitored for 18 months to track changes over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify early signs or predictors of myasthenia gravis, potentially leading to better monitoring or earlier intervention.
What could go wrong
This is an observational study, not a treatment trial. It is small (40 participants) and early-stage, so findings may not apply broadly or lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (≥18 years) undergoing evaluation for thymic abnormalities and/or myasthenia gravis at a tertiary referral center. Participants include individuals with thymoma or other thymic pathology, with or without MG-related antibodies and with or without clinically manifest myasthenia gravis, as well as patients with established myasthenia gravis without evidence of thymic abnormalities. Participants are recruited from routine clinical care settings, including neurology and thoracic surgery units, and reflect a spectrum of clinical and immunological phenotypes relevant to disease development and progression. This population enables the investigation of the relationship between thymic pathology, systemic immune profiles, and neuromuscular junction involvement in myasthenia gravis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years at the time of informed consent * Ability to provide written informed consent and comply with study procedures * Availability of a serum sample for testing MG-related antibodies * Availability of chest imaging (CT and/or MRI) to classify thymic status Participants must also meet the criteria for at least one of the following study groups: Cohort 1: Thymoma with MG-related antibodies * Histologically or radiologically confirmed thymoma * Presence of at least one pathogenic MG-related antibody (AChR) * Presence or absence of clinically manifest myasthenia gravis Cohort 2: Other thymic abnormalities with MG-related antibodies * Imaging or histological evidence of non-thymomatous thymic pathology (e.g., thymic hyperplasia) * Presence of at least one pathogenic MG-related antibody (AChR) * Presence or absence of clinically manifest myasthenia gravis Cohort 3: Thymoma without MG-related antibodies * Histologically or radiologically confirmed thymoma * Negative for pathogenic MG-related antibodies (AChR) * No clinical diagnosis or symptoms suggestive of myasthenia gravis Cohort 4: Myasthenia gravis without thymic abnormalities * Established clinical diagnosis of myasthenia gravis with consistent clinical features, supported by at least one of the following: 1. Seropositivity for MG-related antibodies (AChR, MuSK, or LRP4), or 2. Abnormal neuromuscular transmission demonstrated by SFEMG or RNS, or 3. Improvement of MG signs with treatment such as oral acetylcholinesterase inhibitors, plasma exchange, IVIg, or corticosteroids * Absence of thymic abnormalities on CT or MRI Exclusion Criteria: * Inability to provide informed consent * Other neuromuscular diseases that could interfere with interpretation of clinical or neurophysiological findings * Severe uncontrolled systemic illness that, in the investigator's judgment, may limit participation or confound study outcomes * Any medical or psychiatric condition, or history of substance abuse, that may compromise adherence to study procedures * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myasthenia gravis (MG) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis thymoma thymus gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myasthenia gravis (MG) Myasthenia gravis associated with thymoma Thymoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Ospedale San Raffaele

    Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.